Artiva Biotherapeutics, Inc. announced that the US FDA has cleared the company’s investigational new drug (IND) application for AB-201. AB-201 is an allogeneic HER2-targeted CAR NK cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing.
[Artiva Biotherapeutics, Inc.]